New Form 8-K - Clene Inc. Filed: 2025-08-14 AccNo: 0001437749-25-026690 Size: 717 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: …
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
New Form 8-K/A - Processa Pharmaceuticals, Inc. Filed: 2025-08-14 AccNo: 0001641172-25-023736 Size: 489 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Cryo-Cell International, Inc. Provides Dividend Update